Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PASADENA, Calif., Jan 30, 2008 (BUSINESS WIRE) -- Sanguine Corporation (OTC
Bulletin Board: SGNC - News) is pleased to announce that it will be opening an
office in West Chester, Pennsylvania, to expand its operations and to secure
east coast representation. The West Chester office will house Sanguine's newly
formed life sciences division. The focus of the life sciences division is to
advance SGNC through the development and acquisition of projects and
technologies that will produce revenue for the Company. The West Chester office
will also be increasing the current efforts to commercialize Sanguine's flagship
product, PHER-02.
West Chester is located just outside of Philadelphia, Pennsylvania, an hour from
Baltimore Maryland and an hour and a half from New York City and Washington D.C.
This ideal location is going to give Sanguine much easier access to some of the
largest cities, hospitals and universities in the country.
David Nelson, Sanguine's CFO, said, "The opening of this new office is an
integral component in our strategy to advance Sanguine. We anticipate many good
things coming from this satellite office."
About Sanguine
Sanguine Corporation, a development stage bio-pharmaceutical company, focuses on
the development of an oxygen-carrying synthetic substitute for human red blood
cells and various other areas requiring oxygen profusion. The company is
developing a synthetic red blood cell product, PHER-O2 that consists of
perfluoro-decalin molecules or synthetic red blood cells, purified water, and a
synthetic and fluorinated surfactant to hold the emulsion together. PHER-O2 is
under Phase II clinical trials and has oxygen-carrying capacity.
For information related to the Sanguine Corporation, contact Investor Relations:
Michael Dancy, 801-746-3570, email: medancy@allwest.net, or visit:
www.sanguine-corp.com.
Forward-looking statements in this release are made pursuant to the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that such forward-looking statements involve risks and
uncertainties, including without limitation, continued acceptance of the
Company's products, increased levels of competition for the Company, new
products and technological changes, the Company's dependence on third-party
suppliers, and other risks detailed from time to time in the Company's periodic
reports filed with the Securities and Exchange Commission.
SOURCE: Sanguine Corporation
PASADENA, Calif., Jan 08, 2008 (BUSINESS WIRE) -- Sanguine Corporation (OTC
Bulletin Board: SGNC), a bio-pharmaceutical company focused on the development
of an oxygen-carrying synthetic substitute for human red blood cells and
numerous other areas requiring oxygen profusion, supplies newly manufactured
PHER-O2 to a European Pharmaceutical Company. The group is evaluating PHER-O2
for intravenous applications.
According to a Company spokesperson, should the pre-clinical trials for
intravenous use be successful, the Company would likely move toward a
development agreement with the potential of licensing PHER-O2 as part of a new
procedure. The procedure, which remains unnamed to protect the respective
company's proprietary material, could revolutionize a medical procedure that is
used every day through out the world.
Dr. Thomas C. Drees, Ph.D. - President and CEO - commented, "Management has
identified numerous applications for PHER-O2. Our most recent work as an ex-vivo
510(K) device for the transportation of transplant material is going well,
however we are keen to move into intravenous work, which has widespread
application. We feel this effort can move us swiftly toward this goal."
For information related to the Sanguine Corporation, contact Investor Relations:
Michael Dancy, 801-746-3570, email: medancy@allwest.net, or visit:
www.sanguine-corp.com.
Forward-looking statements in this release are made pursuant to the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that such forward-looking statements involve risks and
uncertainties, including without limitation, continued acceptance of the
Company's products, increased levels of competition for the Company, new
products and technological changes, the Company's dependence on third-party
suppliers, and other risks detailed from time to time in the Company's periodic
reports filed with the Securities and Exchange Commission.
SOURCE: Sanguine Corporation
CONTACT: For Sanguine CorporationMichael Dancy, 801-746-3570 (Investor Relations)medancy@allwest.net
Copyright Business Wire 2008
PASADENA, Calif., Jan 08, 2008 (BUSINESS WIRE) -- Sanguine Corporation (OTC
Bulletin Board: SGNC), a bio-pharmaceutical company focused on the development
of an oxygen-carrying synthetic substitute for human red blood cells and
numerous other areas requiring oxygen profusion, supplies newly manufactured
PHER-O2 to a European Pharmaceutical Company. The group is evaluating PHER-O2
for intravenous applications.
According to a Company spokesperson, should the pre-clinical trials for
intravenous use be successful, the Company would likely move toward a
development agreement with the potential of licensing PHER-O2 as part of a new
procedure. The procedure, which remains unnamed to protect the respective
company's proprietary material, could revolutionize a medical procedure that is
used every day through out the world.
Dr. Thomas C. Drees, Ph.D. - President and CEO - commented, "Management has
identified numerous applications for PHER-O2. Our most recent work as an ex-vivo
510(K) device for the transportation of transplant material is going well,
however we are keen to move into intravenous work, which has widespread
application. We feel this effort can move us swiftly toward this goal."
For information related to the Sanguine Corporation, contact Investor Relations:
Michael Dancy, 801-746-3570, email: medancy@allwest.net, or visit:
www.sanguine-corp.com.
Forward-looking statements in this release are made pursuant to the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that such forward-looking statements involve risks and
uncertainties, including without limitation, continued acceptance of the
Company's products, increased levels of competition for the Company, new
products and technological changes, the Company's dependence on third-party
suppliers, and other risks detailed from time to time in the Company's periodic
reports filed with the Securities and Exchange Commission.
SOURCE: Sanguine Corporation
CONTACT: For Sanguine CorporationMichael Dancy, 801-746-3570 (Investor Relations)medancy@allwest.net
Copyright Business Wire 2008
Sanguine Selects Stuart J. Beebe to the Company's Management Advisory Team
Monday October 22, 6:00 am ET
PASADENA, Calif.--(BUSINESS WIRE)--Sanguine Corporation (OTC Bulletin Board: SGNC), a bio-pharmaceutical company focused on the development of an oxygen-carrying synthetic substitute for human red blood cells and numerous other areas requiring oxygen profusion, selected Stuart J. Beebe to the Company’s management advisory team.
Mr. Beebe recently served as CEO/President of CNL Retirement Properties, Inc., one of the largest health care REITs in the country. Stuart was directly responsible for all strategic business initiatives, including development, acquisitions, and financing projects for the Company. Under his leadership, CNL Retirement Properties opportunistically acquired and developed, during a 32 month period, 280 properties located in 34 states, valued in excess of 3.5 billion. In October of 2006, he championed the sale of the company to Health Care Properties, the nation's largest healthcare REIT for $5.2 billion. Prior to heading CNL, he served as CFO of CNL Real Estate Group in Orlando for four years, after serving for 15 years as Senior VP for the Florida division of Lincoln Property Company.
Dr. Thomas C. Drees, Ph.D. – President and CEO, commented, “We are excited to have Stuart join our team. His experience in the areas of finance, business development, and acquisition negotiations enhances our ability to execute our previously discussed objectives. Our plan is to grow our company organically by completing the FDA approval of PHER-O2; while in parallel, acquiring a private company(s) whose expertise, management and earnings will enable us to move vigorously toward becoming a world class pharmaceutical company.”
Drees added, “During our development of PHER-02 as a blood alternative, we realized its incredible oxygen carrying capabilities. The total market potential for a FDA approved PHER-O2 is estimated at more than $7 billion in the U.S. alone. This would include both intravenous and ex-vivo applications. Currently we are working toward an ex-vivo 510(K) device FDA approval, with intravenous applications slated for the future. We believe that our product is far superior to any other product currently in the industry and represents a major breakthrough. Utilizing our team of experts, both domestically and within Europe, we look forward to add numerous products that work synergistically with our oxygen carrier.”
For information related to the Sanguine Corporation, contact Investor Relations: Michael Dancy, 801-746-3570, email: medancy@allwest.net, or visit: www.sanguine-corp.com.
Forward-looking statements in this release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company’s products, increased levels of competition for the Company, new products and technological changes, the Company’s dependence on third-party suppliers, and other risks detailed from time to time in the Company’s periodic reports filed with the Securities and Exchange Commission.
Contact:
For Sanguine Corporation
Michael Dancy, 801-746-3570 (Investor Relations)
medancy@allwest.net
--------------------------------------------------------------------------------
Source: Sanguine Corporation
Sanguine Corporation Presents a Message to Its Shareholders
Press Release Source: Sanguine Corporation
Tuesday September 25, 6:00 am ET
PASADENA, Calif.--(BUSINESS WIRE)--Sanguine Corporation (OTC Bulletin Board: SGNC - News) presents a message to its shareholders:
Dr Drees, Chairman and CEO of Sanguine stated, "Dear Sanguine Shareholders, let me take this opportunity to bring you current on the many programs that we have been working on during this last year. It has been a very important time for our company. Below you will find a brief overview on the product, PHER-O2, a synthetic red blood cell substitute and oxygen carrier; the current status for its FDA approval; significant changes to our management team; a direction moving our development stage company into a stronger and more diverse position; and what we see as a strong future for our shareholders.
In November of this last year, we completed our pre-Investigation New Device (pre-IND) meeting with the FDA. At this meeting, management presented phase II data and our proposed testing protocol as prepared by our previously announced program management team, including Dr. Shapiro from the University of Alberta in Edmonton. The data presented to the FDA related to Islet Cell transportation in a bath including emulsified PHER-O2. We have completed pre-animal trials as part of the Islet Cell transplant program. The FDA has classified the product as a device, which our management believes should significantly reduce the cost and timeframe of an approval. The FDA requested that follow up information related to a Master Drug File and a Method of Use be completed to support a 510(k) Medical Device application. Management expects this to be completed in the near future; however several important areas have been considered in preparing for the future of Sanguine.
Sanguine Corporation is a bio-pharmaceutical company focused on the development of oxygen-carrying synthetic substitutes for human red blood cells and numerous other areas requiring oxygen perfusion. The Company's current product, PHER-O2 is a second generation to the previously FDA approved Fluosol DA product. The Fluosol approval, led by Dr. Drees, was granted in Canada, the U.K., and Germany, Australia and New Zealand. The goal is to replace the current product used for transporting living tissue, known as UW (University of Wisconsin) solution (trade name: Viaspan(TM)). The availability of vital organs for transplant is severely limited, in part, because many of the systems most commonly used to preserve living tissue are believed to be based on 50-60 year old technologies and remain limited in their usefulness. As a result, organ banks do not have the true capability of storing organs for any significant length of time. The benefit of transporting the living tissue in an Oxygenated bath is believed to be significantly better than the current technology available. Once FDA approval is achieved, Sanguine believes that PHER-O2 will be used in a variety of ways, similar to Fluosol. It is the Company's goal to commence work with the many research programs that have contacted management related to adding PHER-O2 to their programs. These programs are for both intravenous use as well as outside the body similar to the current 510(k) Medical Device approach.
We look forward to talking about these new Collaboration & Product Development programs; however, they relate to new partnerships for sales and/or licensing of PHER-O2. The projects under consideration, and which are planned for collaborative effort, involve the transporting organs, new methods enabling the transport of organs at higher temperatures, further islet cell transportation, and surface wound treatment programs, metabolic imaging, and numerous other programs. Our goal is to complete the FDA 510(k)-device application, and then commence sales and licensing of PHER-O2. In parallel, programs using PHER-O2 internally will be completed. For intravenous use, PHER-O2 would be considered as a Biological agent.
To complete the above programs, we plan increase our management and advisory staff. We have completed the first phase of securing new management. We look forward to talking more about our new team in the future; however, we plan to rapidly move from a company doing research and development of PHER-O2 into a company with an FDA approved product ready for sales, and we are considering new opportunities such as potential acquisitions. When considering the possibility of acquisitions, our management team will ensure that the new company Sanguine is becoming has the ability to provide our employees and shareholders with long-term stability and opportunity.
For information related to the Sanguine Corporation, contact Investor Relations: Michael Dancy, 801-746-3570, email: medancy@allwest.net, or visit: www.sanguine-corp.com.
Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission."
Contact:
Sanguine Corporation,
Investor Relations:
Michael Dancy, 801-746-3570,
medancy@allwest.net
www.sanguine-corp.com.
PS- Tthe stock I was referring to in my prior post is SGNC. Richard
I have been watching this stock since 1999; It's just about ripe. It should be a good one for my Roth IRA. Any one care to guess how long this new direction of Gov-approval might take? Happy Trades; Richard.
PASADENA, Calif., May 08, 2007 (BUSINESS WIRE) -- Sanguine Corporation (OTC
Bulletin Board: SGNC), a bio-pharmaceutical company focused on the development
of an oxygen-carrying synthetic substitute for human red blood cells and
numerous other areas requiring oxygen profusion, in collaboration with its FDA
testing contractors and development team, recently added additional management
contractors to aid in moving the Company through the 510(k) device application
process. The new contractors are intended to aid in managing the 510(k) approval
and capitalization path.
The Company's product manufacturer, a well known pharmaceutical development
company located in Europe, is completing the chemistry, manufacturing and
controls (known as CMC) effort necessary to move PHER-O2 into a position where
large manufactured quantities are possible. This effort is also planned to
support the previously announced FDA requested task of preparing a Master Drug
File submission. According to a Company spokesperson, the Company has had
PHER-O2 prepared in small test-only quantities; however, it is now time to be
able to prepare PHER-O2 in large quantities.
Also as previously announced, the Sanguine team continues its effort in
preparing its protocol for the use of PHER-O2 in human whole organ transplant
tissue (Liver, Kidneys, Heart, Lung, etc.). Following the development of the
transport protocol and the submission of PHER-O2's Master Drug File submission,
the Company plans to file a Medical Device (510-K) application with the FDA.
Once complete for each organ, this designation will enable the sale of PHER-O2
as indicated for the transport of whole organs used in the $12 billion annual
organ and tissue transplantation market in the U.S.
Dr. Thomas C. Drees, Ph.D., President and CEO, commented, "We have been at the
forefront of synthetic blood innovation for the past decade, and continue to
make significant progress in the area. Recently, we received notification from
the FDA that PHER-O2 is (to be) classified as a medical device and not a drug,
which now avails us to apply for approval as such under a 510(k) filing instead
of a full Pre-Market Approval (PMA). We believe that this represents a great
opportunity for the Company inasmuch that we can look forward to a potentially
much shorter path to market."
Drees added, "During our development of PHER-O2 as a blood alternative, we
realized its incredible oxygen carrying capabilities. This led us to determine
that PHER-O2 has multiple prospective additional applications including:
transfusion recipients, heart attack and stroke victims and other applications,
with the intent of seeing that PHER-O2 is in every emergency room (ER) and
ambulance across the U.S. The total market potential for PHER-O2 is estimated at
more than $7 billion in the U.S. alone. We believe that our product is far
superior to any other product currently in the industry and represents a major
breakthrough. We are looking forward to making our FDA application and working
to take Sanguine to the next level."
For information related to the Sanguine Corporation, contact Investor Relations:
Michael Dancy, 801-746-3570, email: medancy@allwest.net, or visit:
www.sanguine-corp.com.
(financialwire.net via COMTEX) -- May 8, 2007 (FinancialWire) Sanguine Corp.
(OTCBB: SGNC), a bio-pharmaceutical company, in collaboration with its Food and
Drug Administration testing contractors and development team, recently added
additional management contractors to aid in moving the company through the 510k
device application process. The new contractors are intended to aid in managing
the 510k approval and capitalization path.
The company's product manufacturer, a pharmaceutical development company located
in Europe, is completing the chemistry, manufacturing, and controls effort
necessary to move PHER-O2 into a position where large manufactured quantities
are possible. This effort is also planned to support the FDA requested task of
preparing a master drug file submission. According to a company spokesperson,
Sanguine has had PHER-O2 prepared in small, test-only quantities.
The Sanguine team is also continuing its effort in preparing its protocol for
the use of PHER-O2 in human whole organ transplant tissue. Following the
development of the transport protocol and the submission of PHER-O2's master
drug file submission, the company plans to file a medical device application
with the FDA. Once complete for each organ, this designation will enable the
sale of PHER-O2 as indicated for the transport of whole organs used in the $12
billion annual organ and tissue transplantation market in the U.S.
Income Statement
http://finance.yahoo.com/q/is?s=sgnc.ob
Sanguine Receives FDA Meeting Minutes to Define PHER-O2 Regulatory Path
TUESDAY, JANUARY 23, 2007 6:00 AM
PASADENA, Calif., Jan 23, 2007 (BUSINESS WIRE) -- Sanguine Corporation (SGNC) , a bio-pharmaceutical company focused on the development of an oxygen-carrying synthetic substitute for human red blood cells and numerous other areas requiring oxygen profusion, in collaboration with its FDA testing contractors and development team, received its meeting minutes letter from the FDA related to the Company's regulatory approval path. The Company is pleased to announce that it is complete with its animal testing program and is preparing to complete the manufacturing process to support PHER-O2's Master Drug File (MDF) submission to the FDA. Information related to Drug Master Files may be found at: http://www.fda.gov/cder/guidance/dmf.htm.
Furthermore, the Sanguine team is preparing its protocol for the use of PHER-O2 in human whole organ transplant tissue (Liver, Kidneys, Heart, Lung, etc...) as detailed by the Company's meeting minutes. Following the development of the transport protocol and the submission of PHER-O2's MDF, the Company plans to file a Medical Device 510(k) application. Once complete for each organ, this designation will enable the sale of PHER-O2 as indicated for the transport of whole organs used in the 12 billion-dollar annual organ and tissue transplantation market in the U.S.
Dr. Thomas C. Drees, Ph.D. - President and CEO added, "Our medical advisory team is to be commended related to the effort necessary to support the FDA meeting. We are excited to finally have a clear path toward our 510(k) application and potential approval for product sales. Although we will not know the final time-line for the submission until we have completed the manufacturing study and the human protocol, our team is in agreement that the total process should be substantially shorter than originally planned when considering intravenous use of PHER-O2. We look forward to announcing further updates, as they become available."
For information related to the Sanguine Corporation, contact Investor Relations: Michael Dancy, 801-746-3570, email: medancy@allwest.net, or visit: www.sanguine-corp.com.
Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
SOURCE: Sanguine Corporation
For Sanguine Corporation
Michael Dancy, 801-746-3570 (Investor Relations)
e-mail: medancy@allwest.net
www.sanguine-corp.com
Copyright Business Wire 2007
CORRECTING and REPLACING Sanguine Meets with FDA To Define PHER-O2 Regulatory Path
PASADENA, Calif., Dec 06, 2006 (BUSINESS WIRE) -- Second graph, first sentence
of release dated Dec. 5, 2006 should read: PIRIBO, a well known BioPharma
Industry analyst, reported that the annual organ and tissue transplantation
market in the U.S. was estimated at $11.7 billion in 2005 and is expected to
rise at an average annual growth rate (AAGR) of 5.2% to $15.1 billion by 2010
(sted PRIBO, a well known BioPharma Industry analyst, reported that the annual
organ and tissue transplantation market in the U.S. was estimated at $11.7
billion in 2005 and is expected to rise at an average annual growth rate (AAGR)
of 5.2% to $15.1 billion by 2010.)
The corrected release reads:
SANGUINE MEETS WITH FDA TO DEFINE PHER-O2 REGULATORY PATH
Sanguine Corporation (OTC Bulletin Board: SGNC), a bio-pharmaceutical company
focused on the development of an oxygen-carrying synthetic substitute for human
red blood cells and numerous other areas requiring oxygen profusion, in
collaboration with its FDA testing contractors and development team, met with
the FDA to discuss the Company's regulatory path. The Company believes that its
product, PHER-O2, is appropriately suited for whole organ (pancreas and kidney),
preservation for transplantation.
PIRIBO, a well known BioPharma Industry analyst, reported that the annual organ
and tissue transplantation market in the U.S. was estimated at $11.7 billion in
2005 and is expected to rise at an average annual growth rate (AAGR) of 5.2% to
$15.1 billion by 2010. The transplantation market was estimated at just under $5
billion in 2005 and is expanding at an AAGR of 4.8%. The fastest growing sector
is small bowel (intestine) transplantation. Kidney and liver transplantation
will account for 78% of the total in 2005. The U.S. tissue transplantation
market totaled about $6.8 billion in 2005. It is projected to grow at an AAGR of
5.5%, to $8.9 billion in 2010. A copy of the report may be found at:
www.piribo.com/publications/biotechnology/organ_tissue_
transplantation_alternatives.html (Due to its length, this URL may need to be
copied/pasted into your Internet browser's address field. Remove the extra space
if one exists.)
Dr. Thomas C. Drees, Ph.D. - President and CEO remarked, "We are extremely
excited to have finally met with the FDA related to our testing program. As I
have mentioned previously, the use of PHER-O2 for pancreas and/or islet cell
preservation in treating diabetes (the fastest growing disease in the world) is
particularly attractive because the product is used ex-vivo (outside the body),
which should simplify the regulatory process. We are most interested in
generating a device indication that presumably would be the most expedient route
toward our ability to market PHER-O2. As indicated by numerous BioPharma
sources, the transplantation market is substantially large. Our plan is to use
PHER-O2 in conjunction with other transplantation transport materials to provide
an oxygenated environment to aid in the longevity of whole organs. We look
forward to having our development team continue its work with the FDA to
finalize the most appropriate and direct regulatory path. We feel the meeting
with the FDA was quite successful."
For information related to the Sanguine Corporation, contact Investor Relations:
Michael Dancy, 801-746-3570, email: medancy@allwest.net, or visit:
www.sanguine-corp.com.
Forward-looking statements in this release are made pursuant to the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that such forward-looking statements involve risks and
uncertainties, including without limitation, continued acceptance of the
Company's products, increased levels of competition for the Company, new
products and technological changes, the Company's dependence on third-party
suppliers, and other risks detailed from time to time in the Company's periodic
reports filed with the Securities and Exchange Commission.
SOURCE: Sanguine Corporation
CONTACT: For Sanguine CorporationMichael Dancy, 801-746-3570 (Investor Relations)e-mail: medancy@allwest.netwww.sanguine-corp.com
Copyright Business Wire 2006
PASADENA, Calif., Dec 05, 2006 (BUSINESS WIRE) -- Sanguine Corporation (OTC
Bulletin Board: SGNC), a bio-pharmaceutical company focused on the development
of an oxygen-carrying synthetic substitute for human red blood cells and
numerous other areas requiring oxygen profusion, in collaboration with its FDA
testing contractors and development team, met with the FDA to discuss the
Company's regulatory path. The Company believes that its product, PHER-O2, is
appropriately suited for whole organ (pancreas and kidney), preservation for
transplantation.
PRIBO, a well known BioPharma Industry analyst, reported that the annual organ
and tissue transplantation market in the U.S. was estimated at $11.7 billion in
2005 and is expected to rise at an average annual growth rate (AAGR) of 5.2% to
$15.1 billion by 2010. The transplantation market was estimated at just under $5
billion in 2005 and is expanding at an AAGR of 4.8%. The fastest growing sector
is small bowel (intestine) transplantation. Kidney and liver transplantation
will account for 78% of the total in 2005. The U.S. tissue transplantation
market totaled about $6.8 billion in 2005. It is projected to grow at an AAGR of
5.5%, to $8.9 billion in 2010. A copy of the report may be found at:
www.piribo.com/publications/biotechnology/organ_tissue_
transplantation_alternatives.html (Due to its length, this URL may need to be
copied/pasted into your Internet browser's address field. Remove the extra space
if one exists.)
Dr. Thomas C. Drees, Ph.D. - President and CEO remarked, "We are extremely
excited to have finally met with the FDA related to our testing program. As I
have mentioned previously, the use of PHER-O2 for pancreas and/or islet cell
preservation in treating diabetes (the fastest growing disease in the world) is
particularly attractive because the product is used ex-vivo (outside the body),
which should simplify the regulatory process. We are most interested in
generating a device indication that presumably would be the most expedient route
toward our ability to market PHER-O2. As indicated by numerous BioPharma
sources, the transplantation market is substantially large. Our plan is to use
PHER-O2 in conjunction with other transplantation transport materials to provide
an oxygenated environment to aid in the longevity of whole organs. We look
forward to having our development team continue its work with the FDA to
finalize the most appropriate and direct regulatory path. We feel the meeting
with the FDA was quite successful."
For information related to the Sanguine Corporation, contact Investor Relations:
Michael Dancy, 801-746-3570, email: medancy@allwest.net, or visit:
www.sanguine-corp.com.
Forward-looking statements in this release are made pursuant to the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that such forward-looking statements involve risks and
uncertainties, including without limitation, continued acceptance of the
Company's products, increased levels of competition for the Company, new
products and technological changes, the Company's dependence on third-party
suppliers, and other risks detailed from time to time in the Company's periodic
reports filed with the Securities and Exchange Commission.
SOURCE: Sanguine Corporation
CONTACT: For Sanguine CorporationMichael Dancy, 801-746-3570 (Investor Relations)e-mail: medancy@allwest.netwww.sanguine-corp.com
Copyright Business Wire 2006
read this Letter on Sanguine's site
http://www.sanguine-corp.com/images/Shareholder%20Let%20Final.pdf
Sanguine Corporation CEO Featured in Exclusive Interview With WallSt.net
THURSDAY, OCTOBER 26, 2006 7:00 AM
- PR Newswire
SGNC
0.10 n/a
NEW YORK, Oct 26, 2006 /PRNewswire via COMTEX/ -- On October 24, Dr. Thomas Dress, Chief Executive Officer for Sanguine Corporation (SGNC) updated the investment community in an exclusive interview with www.wallst.net. Topics covered in the interview include an overview of the Company and the markets it serves, recent press releases, current capitalization, upcoming strategic and financial milestones.
To hear the interview in its entirety, visit www.wallst.net , and click on "Interviews." Interviews require free registration, and can be accessed either by locating the respective company's ticker symbol under the appropriate exchange on the left-hand column of the "Interviews" section of the site, or by entering the respective company's ticker symbol in the Search Archive window.
About Sanguine Corporation:
Sanguine Corporation is a public company based in Pasadena, California, whose primary focus is the development of PHER-O2, a perfluorocarbon (PFC) emulsion with oxygen carrying properties that has immediate applications as an intravenous supplement to red blood cell function. For more information, please visit the company website at www.sanguine-corp.com .
About WallSt.net:
www.wallst.net is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. The website is a leading provider of financial news, media, tools and community-driven applications for investors. www.wallst.net offers visitors free membership to its in-depth executive interviews, exclusive editorial content, breaking news, and several proprietary applications. In addition to its website, WallStreet Direct organizes investor conferences, publishes a newspaper, and provides multimedia advertising solutions to small and mid-sized publicly traded companies. We are expecting to receive two hundred eighty dollars from Sanguine Corporation for the dissemination of this press release. For a complete list of our advertisers, and advertising relationships, visit http://www.wallst.net/disclaimer/disclaimer.asp .
SOURCE WallStreet Direct, Inc.
Nick Iyer of Digital Wall Street, Inc., +1-800-4-WALL-ST
http://www.wallst.net
Copyright (C) 2006 PR Newswire. All rights reserved
I have owned shares in this company Since 2004. I'm waiting to see if it makes head way. there are positives in it. The FDA plan is going ahead and they have responded to my emails. the application of the product in keeping islet cells alive for transplant is very important in the fight against diabetes. if this company can suceed in the FDA trails it will push this company through the roof.
Manny
What do you make of this company? Do you think they will actually get if off the ground?
Curios as to your thoughts? Do you own any shares?
Beans
Posted on: Tuesday, 7 February 2006, 06:00 CST
Sanguine Evaluates a New Science Approach to Use PHER-O2 in Conjunction With Type 2 Diabetes Therapies
Sanguine Corp. (OTCBB: SGNC), a bio-pharmaceutical company focused on the development of oxygen-carrying synthetic substitutes for human red blood cells and numerous other areas requiring oxygen perfusion, was presented a new scientific approach by an international medical group whereby PHER-O2 would be used to increase oxygenation to the small vessels that supply blood to critical areas of the body affected by Type 2 diabetes. Dr. Robert Kwun, a board-certified surgeon, is evaluating the science for the Sanguine medical team.
Kwun remarked, "The Sanguine product, PHER-O2, has long been viewed by us as a blood substitute. However, when considering the oxygen-carrying capacity associated with the product's predecessor, FDA-approved Fluosol, it's reasonable that PHER-O2 could be beneficial to many medical situations where increased oxygen into the microvascular system is desired. In addition to the Edmonton protocol and PHER-O2 work, which are for type 1 diabetics, it follows that efforts to evaluate science, which could aid type 2 diabetics directly, compliments the company's expanded business direction involving diabetes therapies. I look forward to evaluating this science to determine if PHER-O2 can play a role."
Dr. Thomas C. Drees, Ph.D., president and CEO, added, "The worldwide market for diabetic therapies, both type 1 and type 2, is huge. According to industry sources, the diabetes market is believed to top 10 billion dollars annually and growing. We are anxious and happy to consider any science where PHER-O2 may play a beneficial role in diabetic medical therapies. Our team looks forward to Dr. Kwun's findings."
For information related to the Sanguine Corp., contact Investor Relations: Michael Dancy, 801-746-3570, e-mail: medancy@allwest.net, or visit: www.sanguine-corp.com.
Quarterly Literature Update
The following contains the quarterly summary of peer-reviewed publications related “exclusively” to ANH for the months of July to September 2006, (and a few publications missed during the prior quarter) taken from the National Library of Medicine databases. My commentary (italics) may be added to reports of special import. NLIM now lists abstracts before they are formally published, as “Epubs.” For simplicity, Epubs are listed separately.
Bennett J et al: Acute normovolemic hemodilution in moderate blood loss surgery: a randomized controlled trial. Transfusion, Volume 46, pages 1097-1103. (PMID: 16836555) Patients undergoing elective hip surgery wee randomized to either ANH or a standard transfusion group. Blood transfusion requirements did not differ significantly between groups. However, infective complications were lower in the ANH group.
Cabrales P et al: Blood viscosity maintains microvascular conditions during normovolemic anemia independent of blood oxygen-carrying capacity. American Journal of Physiology Heart and Circulatory Physiology, Volume 291, pages H581-590. (PMID: 16517943) Another hamster window microcirculation study from this prolific group in which effects of ANH on viscosity and oxygen delivery were studied. In this study, decreased microcirculatory conditions associated with ANH were secondary to decreased viscosity, not decreased oxygen delivery.
Epstein NE et al: Impact of intraoperative normovolemic hemodilution on transfusion requirements for 68 patients undergoing lumbar laminectomies with instrumented posterolateral fusion. Spine, Volume 31, pages 2227-2230 with discussion on page 2231. (PMID: 16946658) The effect of ANH on allogeneic transfusion was studied in patients undergoing extensive spine surgery. The majority of patients required no allogeneic blood, although this study is seriously flawed from a methodological standpoint.
Farina JA et al: Comparative study of isovolemic hemodilution with 3% albumin, dextran-40, and prophylactic enoxaparin (LMWH) on thrombus formation at venous microanastomosis in rats. Microsurgery, Volume 26, pages 456-464. (PMID: 16924631) A rodent study that compared ANH with albumen or dextran with fractionated heparin in reducing thrombus formation in venous anastomosis. ANH with albumen was the most effective antithrombotic agent.
Han SH et al: The effect of esmolol-induced controlled hypotension in combination with acute normovolemic hemodilution on cerebral oxygenation. Acta Anaesthesiologica Scandinavica, Volume 50, pages 863-868. (PMID: 16879470) The effect of ANH and controlled hypotension on cerebral oximetry was studied in patients undergoing orthopedic surgery. Controlled hypotension plus ANH was associated with lower regional oxygen saturation indices compared to ANH alone.
Huang Y et al: PEGylated albumin-heme as an oxygen-carrying plasma expander: Exchange transfusion into acute anemia rat model. Biomaterials, Volume 27, pages 4477-4483. (PMID: 16678256) A study in rats using ANH to simulate a hemorrhagic state, examined the effect of a novel PEgylated albumen heme on various parameters of oxygen transport. The PEGylated solution functioned as an effective oxygen-carrying plasma expander.
Jabbour N et al: Impact of a transfusion-free program on non-Jehovah's Witness patients undergoing liver transplantation. Archives of Surgery, Volume 141, pages 913-917. (PMID: 17001788) Since the inception of the transfusion-free liver transplantation program at USC – LA, 239 orthotopic liver transplants were performed. Compared to an earlier control group, the transfusion-free program has reduced allogeneic transfusion rates.
Loubser PG: Needleless adaptation to blood collection bags used for acute normovolemic hemodilution. Anesthesia Analgesia, Volume 103, pages 491-492. (PMID: 1686144) Letter describing a modification of blood collection bags used for ANH.
Mathru M et al: Splanchnic oxygen consumption is impaired during severe acute normovolemic anemia in anesthetized humans. Anesthesiology, Volume 105, pages 37-44. (PMID:16809992) They induced ANH to a Hb of 6 g/dl, in patients undergoing spine or abdominal surgery, studying several parameters of splanchnic oxygen delivery and consumption. Splanchnic oxygen consumption was impaired and oxygen delivery decreased, suggesting that the risk to the GI tract during ANH is substantial.
Morariu AM et al: Acute isovolemic hemodilution triggers proinflammatory and procoagulatory endothelial activation in vital organs: role of erythrocyte aggregation. Microcirculation, Volume 13, pages 397-409. (PMID: 16815825) A porcine study examining erythrocyte aggregation and endothelial activation during ANH. Erythrocyte aggregation was reduced during ANH. The findings suggest an endothelium-dependent thrombogenic response may occur in the microcirculation during ANH.
Ramnarine IR et al: Autologous blood transfusion for cardiopulmonary bypass: effects of storage conditions on platelet function. Journal of Cardiothoracic and Vascular Anesthesia, Volume 20, pages 541-547. (PMID: 16884986) Platelet function (impedance aggregometry) of ANH blood stored in citrate or heparinized blood bags at room temperature was studied in 27 patients undergoing CABG surgery. Platelet function was reduced by storage in both agents, although more with heparin. Even after reinfusion, platelet function in vivo was reduced. The authors conclude that ANH whole blood should not be stored in citrate. Scharbert et al, Anesth Analg, Volume 102, pages 1280-4, 2006, reported that platelets stored at room temperature were associated with marked inhibition of platelet aggregation. This effect was absent when platelets were stored near 37oC. So, are Ramnarine’s findings secondary to temperature, citrate, heparin or both?
Ruttmann TG et al: The haemodilution enhanced onset of coagulation as measured by the thrombelastogram is transient. European Journal of Anaesthesiology, Volume 23, pages 574-579. (PMID: 16507197) Volunteers were subjected to hemodilution by rapidly infusing crystalloid. TEG showed faster onset of coagulation, while antithrombin levels decreased.
Shander A et al: The long and winding road of acute normovolemic hemodilution. Transfusion, Volume 46, pages 1075-9. (PMID: 16836551) An editorial comment on the study by Bennett et al, above, in the same Journal.
Sharma V et al: Evaluation of Epsilon amino-caproic acid (EACA) and autologous blood as blood conservation strategies in patients undergoing cardiac surgery. Heart, Lung and Circulation, Volume 15, 261-265. (PMID: 16698318) They compared two groups of patients undergoing cardiac surgery. ANH was performed in one group while EACA was used in the other. No difference was found between groups with respect to allogeneic transfusion. However, this study is seriously flawed from a methodological standpoint.
Verdin-Vasquez RC et al : Use of perftoran emulsion to decrease allogeneic blood transfusion in cardiac surgery: clinical trial. Artificial Cells Blood Substitutes Immobilization Biotechnology, Volume 34, pages 433-454. (PMID: 16818416) The PFC perftoran was used in conjunction with ANH in 30 patients undergoing cardiac surgery. Compared to controls, the Perftoran patients manifested a higher PaO2 and required less allogeneic blood
Dear Manny,
The product PHER-O2 is in its pre IND phase with Cardinal Health and the
University of Alberta. The company has heard from the FDA and the FDA has
determined that the trial approach is as a device, which I understand from
Cardinal is a very good thing.
Best regards
Michael Dancy
took a long time but this puppy finally started moving from that .13 level
nice!
Looks interesting.
Sanguine Files for Additional Patent Coverage on Its Oxygen Carrier, PHER-O2
August 09, 2005 06:30:01 (ET)
PASADENA, Calif., Aug 09, 2005 (BUSINESS WIRE) -- Sanguine Corp. (SGNC, Trade), a bio-pharmaceutical company focused on the development of an oxygen-carrying synthetic substitute for human red blood cells and numerous other areas requiring oxygen profusion, has filed for additional patent coverage detailing the specific formulation for its current product, PHER-O2. Dr. Thomas C. Drees, Ph.D., Sanguine's president and CEO, has received an approved patent for the use of a perfluorodecalin, a key component of PHER-O2, for use as a blood substitute; however, the patent recently filed incorporates additional critical materials used to formulate PHER-O2 and language depicting PHER-O2 as an oxygen carrier for use as a red blood cell enhancer and a transportation medium for diabetic islet cell transplantation. Further, the U.S. Patent Office filing assigns the patent rights of PHER-O2 to Dr. Drees and the Sanguine Corp.
Dr. Drees remarked, "For more than a decade we have worked on the development of an oxygen carrier that has properties surpassing those of Fluosol D.A., which received its FDA approval under my management. At Alpha Therapeutics, we received FDA approval for Fluosol; however, there were some drawbacks, including the need to keep the product frozen and to keep it in multiple components to maintain its shelf life. The new formulation, PHER-O2, is believed to have the ability to be stored at room temperature and in a pre-mixed form, where it will remain stable for long periods of time. This is critical to the potential deployment of PHER-O2 in ambulances and other nonrefrigerated environments. Additionally, we are completing our pre-clinical study with Beckloff and Associates, a division of Cardinal Health, where the company will pursue an FDA approval using PHER-O2 as a transport medium for the diabetic transplant of islet cells. Beckloff has completed its evaluation study of Fluosol and PHER-O2. Now that the additional patents have been filed for, we look forward to releasing information on our testing program in the near future."
Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the company's products, increased levels of competition for the company, new products and technological changes, the company's dependence on third-party suppliers, and other risks detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission.
SOURCE: Sanguine Corp.
lol... i was thinking about starting an SGNC board a couple weeks ago...
looks good
It is hard to keep up with one board,,I used to do three on Sanguine...
for Teds benifit....GO TEAM GO! RAW RAW RAW...lol
there ya go Ted,,, I doubt I will be hangin around here,,
I think I will stay where I'm at...
See Ya
Mr Prospector....
Thank you, I see this stock shall be a fun one soon.
Followers
|
5
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
132
|
Created
|
06/09/05
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |